Description     Claims     Drawing  

US61880717   [0001] 
WO2013132354A2   [0004]  [0004] 
US5494810A   [0040] 
US5639611A   [0040] 
US5965408A   [0040] 
US7662594B   [0040] 
US5773258A   [0040] 
US5338671A   [0040] 
US5508169A   [0040] 
WO05023091A2   [0040] 
US20070202525   [0040] 
US6110684A   [0041] 
US5958692A   [0041] 
US5851770A   [0041] 
US5849481A   [0041] 
US5710264A   [0041] 
US5124246A   [0041] 
US5624802A   [0041] 
US6210884B   [0041] 
US6183960B   [0041] 
US6235502B   [0041] 
US5409818A   [0041] 
US6150097A   [0041] 
US6248229B   [0041] 
US6221583B   [0041] 
US6013170A   [0041] 
US6063573A   [0041] 
US5403711A   [0041] 
US5011769A   [0041] 
US5660988A   [0041] 
US6121001A   [0041] 
US6110677A   [0041] 
US5914230A   [0041] 
US5882867A   [0041] 
US5792614A   [0041] 
US5288609A   [0041] 

Clinical Cancer Research   [0004] 
Nucleic Acids Res.   [0040] 
Nucleic Acids Research   [0040] 
PNAS   [0040] 
Nucleic Acids Research   [0040] 
Nucleic Acids Research   [0040] 
Human Genetics   [0040] 
BMC Genetics   [0040] 
Nucleic Acids Research   [0040] 
Biotechnology   [0040] 
Biotechnology   [0040] 
J. Molecular Endocrinology   [0040] 
Nucleic Acids Research   [0040] 
Biotechniques   [0040] 
Biotechniques   [0040] 
Nucleic Acids Research   [0040] 
Proc Natl Acad Sci USA.   [0040] 
Proc. Natl. Acad. Sci USA   [0041] 
The Spread of Tumors in the Human Body   [0045] 
Early Breast Cancer Trialists' Collaborative.   [0060] 
Lancet   [0060] 
Nature   [0061] 
Nature   [0061] 
Cancer Cell   [0061]  [0095] 
Clin Cancer Res   [0061] 
Clin Cancer Res   [0085]  [0100] 
N Engl J Med   [0085]  [0103] 
Neoplasia   [0088] 
Radiat Res   [0088] 
Cancer Cell   [0089] 
Mol Cancer Res   [0095] 
Clin Cancer Res.   [0105] 
Cancer statistics   [0106] 
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials   [0106] 
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications   [0106] 
Repeated observation of breast tumor subtypes in independent gene expression data sets   [0106] 
Comprehensive molecular portraits of human breast tumours   [0106] 
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group   [0106] 
Validation of a radiosensitivity molecular signature in breast cancer   [0106] 
A gene-expression signature to predict survival in breast cancer across independent data sets   [0106] 
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer   [0106] 
Prediction of radiation sensitivity using a gene expression classifier   [0106] 
Search for a gene expression signature of breast cancer local recurrence in young women   [0106] 
Genetic alterations and oncogenic pathways associated with breast cancer subtypes   [0106] 
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes   [0106] 
A gene-expression signature as a predictor of survival in breast cancer   [0106] 
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials   [0106] 
Mutational landscape and significance across 12 major cancer types   [0106] 
Discovery and saturation analysis of cancer genes across 21 tumour types   [0106] 
Comparison of features of human breast cancer cell lines and their corresponding tumors   [0106] 
Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining   [0106] 
The mechanism of action of radiosensitization of conventional chemotherapeutic agents   [0106] 
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance   [0106] 
Use of archived specimens in evaluation of prognostic and predictive biomarkers   [0106] 
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition   [0106] 
Mean inactivation dose: a useful concept for intercomparison of human cell survival curves   [0106] 
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer   [0106]